Mounjaro vs Retatrutide: Long-Term Durability of Response

What Is the Core Mechanism Difference Between Mounjaro and Retatrutide?

Tirzepatide targets two receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Retatrutide targets three: GIP, GLP-1, and the glucagon receptor (GCGR). That third receptor is the primary pharmacological distinction, and it may explain why Phase 2 weight loss numbers with retatrutide exceeded those seen with tirzepatide at comparable timepoints.

How GIP/GLP-1 Dual Agonism Works in Tirzepatide

Tirzepatide's dual mechanism increases insulin secretion in a glucose-dependent fashion while suppressing glucagon and slowing gastric emptying. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points and body weight by 11.2 kg at 40 weeks compared with semaglutide 1 mg, which reduced weight by 5.3 kg over the same period 1. These effects persisted well beyond the 40-week primary endpoint in extension analyses.

GIP receptor agonism appears to potentiate GLP-1 signaling in adipose tissue and the central nervous system. A 2022 mechanistic study in Diabetes confirmed that GIP co-agonism amplifies energy balance effects beyond what GLP-1 alone achieves 2.

How Triple Agonism Works in Retatrutide

Retatrutide adds glucagon receptor activation on top of the GIP/GLP-1 base. Glucagon stimulates hepatic glucose output, but at the systemic level it also increases thermogenesis and resting energy expenditure. The theoretical concern about glucagon-induced hyperglycemia is partially offset by the concurrent GLP-1 component, which suppresses endogenous glucagon secretion.

In the Phase 2 dose-finding trial (Jastreboff et al., NEJM 2023, N=338), participants receiving retatrutide 12 mg lost a mean of 24.2% body weight at 48 weeks, compared with 2.1% in the placebo group (P<0.001) 3. The 8 mg cohort lost 22.8%. These figures exceed any weight loss seen at a comparable timepoint in tirzepatide Phase 3 data.

What Does the Durability Evidence Show for Tirzepatide?

Tirzepatide has the most mature long-term dataset of any approved incretin-based weight management drug. The SURMOUNT program spans four major trials, with SURMOUNT-1 providing the primary durability evidence.

SURMOUNT-1: 72-Week Weight Loss Data

SURMOUNT-1 (N=2,539, non-diabetic adults with obesity) showed that tirzepatide 15 mg produced a mean 20.9% reduction in body weight at 72 weeks versus 3.1% with placebo 4. The 10 mg and 5 mg doses produced 19.5% and 15.0% reductions, respectively. Critically, weight loss curves had not fully plateaued by week 72, suggesting continued response with ongoing treatment.

At 36 weeks the 15 mg group had lost approximately 15%, meaning roughly one-third of the total weight loss occurred between weeks 36 and 72. This late-phase loss pattern distinguishes tirzepatide from earlier GLP-1 agents where plateaus typically arrived by week 36.

SURMOUNT-4: What Happens When Tirzepatide Stops

SURMOUNT-4 (N=783) enrolled participants who had already lost weight on open-label tirzepatide for 36 weeks, then randomized them to continue tirzepatide or switch to placebo for 52 additional weeks. Those who continued tirzepatide lost an additional 5.5% of body weight. Those switched to placebo regained 14.8% 5. This rebound finding establishes that tirzepatide's weight loss is not durable without continued treatment, a point directly relevant to any comparison with investigational agents.

SURPASS-CVOT and Cardiovascular Durability

The SURPASS-CVOT trial examined tirzepatide versus insulin degludec in 1,995 patients with type 2 diabetes over approximately 104 weeks. Tirzepatide maintained superior glycemic control and weight reduction throughout, with HbA1c differences remaining stable from week 52 onward 6. Sustained cardiometabolic improvements alongside weight loss reinforce the long-term benefit profile beyond the scale alone.

What Does the Durability Evidence Show for Retatrutide?

Retatrutide's durability story is still being written. Only Phase 2 data exist in the peer-reviewed literature as of mid-2025.

Phase 2 Trial: 48-Week Trajectory

The Jastreboff et al. Phase 2 trial ran 48 weeks with a 4-week follow-up after drug discontinuation 3. At 48 weeks, the weight loss curve for the 12 mg dose had not fully plateaued, mirroring what tirzepatide showed in SURMOUNT-1. This non-plateau trajectory at 48 weeks may indicate that retatrutide's durability window extends considerably further. No 72-week or longer data are published.

The glucagon receptor component is also being watched for hepatic effects. In Phase 2, modest reductions in liver fat were observed via MRI-PDFF in a subset analysis, which may matter for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) 3.

Phase 3 Program: What to Expect

Eli Lilly has initiated TRIUMPH Phase 3 trials for retatrutide across obesity, type 2 diabetes, and cardiovascular indications. Primary completion dates for the obesity key trial extend into late 2025 and 2026. Until those data publish, no meaningful 72-week or longer durability comparison between retatrutide and tirzepatide is possible. Any claim of superior long-term durability for retatrutide remains hypothetical based on Phase 2 trajectory alone.

Head-to-Head Comparison: What Trial Data Actually Allow

No randomized head-to-head trial comparing tirzepatide and retatrutide has been published. Comparisons must be interpreted with caution because the trials differ in population, duration, dose titration schedules, and primary endpoints.

Weight Loss Benchmarks Side by Side

| Timepoint | Tirzepatide 15 mg | Retatrutide 12 mg | Population | |---|---|---|---| | 24 weeks | ~13% (SURMOUNT-1) | ~17.3% (Phase 2) | Adults with obesity | | 36 weeks | ~15% (SURMOUNT-1) | ~21% (Phase 2, extrapolated) | Adults with obesity | | 48 weeks | ~18% (SURMOUNT-1) | 24.2% (Phase 2) | Adults with obesity | | 72 weeks | 20.9% (SURMOUNT-1) | No data | Adults with obesity |

The Phase 2 trial for retatrutide enrolled 338 participants versus 2,539 in SURMOUNT-1. Smaller Phase 2 trials often show larger effect sizes that partially attenuate in Phase 3 populations. Whether retatrutide's 24.2% at 48 weeks will replicate at scale is a genuine empirical question.

Gastrointestinal Side-Effect Profile

Nausea, vomiting, and diarrhea were the most common adverse effects in both trials. In SURMOUNT-1, nausea affected 31.0% of participants on tirzepatide 15 mg versus 16.4% on placebo 4. In the retatrutide Phase 2 trial, nausea rates at the 12 mg dose were approximately 45%, higher than tirzepatide 3. Whether this difference persists after slower titration protocols in Phase 3 is unknown.

Glycemic Effects in Type 2 Diabetes

Tirzepatide's glycemic profile in type 2 diabetes is documented across the full SURPASS program. SURPASS-2 showed a 2.46 percentage point HbA1c reduction at 40 weeks 1. Retatrutide's Phase 2 diabetes cohort data are limited. The glucagon agonist component theoretically raises concern about glycemic stability, though the GLP-1 component appears to compensate adequately based on Phase 2 signal 7.

How Does Weight Loss Plateau Timing Differ Between the Two Drugs?

Plateau timing determines practical durability. A drug that continues producing weight loss at 72 weeks has different dose-management implications than one that plateaus at 36.

Tirzepatide's Plateau Pattern

Analysis of SURMOUNT-1 weight loss curves shows the rate of loss slowing progressively after week 36, with approximate plateau around weeks 60 to 72 at the 15 mg dose 4. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that "titrating to the highest tolerated dose and maintaining treatment is necessary to sustain benefits" 8. This is consistent with the plateau data: once maximum tolerated dose is reached and maintained, weight stabilizes rather than continuing to decline.

Retatrutide's Projected Plateau

Based on the Phase 2 curve shape, the retatrutide 12 mg group had not fully plateaued by week 48. If the trajectory follows the pattern seen with tirzepatide, a true plateau may not arrive until week 60 to 72 or beyond. This is pharmacologically plausible given the additional glucagon-mediated thermogenic mechanism that could sustain a higher metabolic rate over a longer period. But this remains inference, not Phase 3 evidence.

Should You Switch from Mounjaro to Retatrutide?

Switching from tirzepatide to retatrutide is not currently possible for most patients outside of clinical trials. Retatrutide does not hold FDA approval as of mid-2025.

Clinical Scenarios Where a Switch Might Be Considered

A switch may become clinically reasonable once retatrutide receives approval in three specific situations. First, a patient who has plateaued on maximum-dose tirzepatide (15 mg) and requires further weight loss for a clinical endpoint, such as pre-surgical BMI reduction. Second, a patient with significant hepatic steatosis who might benefit from the GCGR-mediated hepatic fat reduction seen in Phase 2. Third, a patient tolerating tirzepatide well who, after counseling on the less mature safety record of retatrutide, prefers to escalate to a newer agent.

The American Association of Clinical Endocrinology (AACE) recommends that medication changes in obesity management "be driven by clinically meaningful endpoints and patient-specific risk-benefit assessment, not by switching for novelty" 9.

Clinical Scenarios Where Staying on Tirzepatide Makes Sense

Patients who have not yet titrated to 15 mg tirzepatide, who have type 2 diabetes with well-controlled HbA1c on the current regimen, or who are within 12 months of starting tirzepatide and have not yet reached plateau should remain on tirzepatide. The evidence base for tirzepatide's cardiovascular benefit is growing. The SELECT-like data for tirzepatide in heart failure (SUMMIT trial, N=731) showed a 38% reduction in the composite of cardiovascular death or worsening heart failure 10. No comparable cardiovascular outcome data exist for retatrutide.

What Are the Rebound Risks for Both Drugs?

Weight regain after stopping either drug is the most clinically relevant durability question for patients. The data on rebound are clearer for tirzepatide.

Tirzepatide Rebound: SURMOUNT-4 Evidence

SURMOUNT-4 found that participants who discontinued tirzepatide after 36 weeks of treatment regained 14.8% of body weight over the following 52 weeks, partially reversing the mean 20.9% total loss achieved on drug 5. By contrast, those who continued tirzepatide lost an additional 5.5%. This pattern is consistent with what has been seen with semaglutide in the STEP-4 withdrawal study, where 63.9% of lost weight was regained within 52 weeks of stopping the drug 11.

Retatrutide Rebound: What Phase 2 Showed

The short 4-week follow-up after drug discontinuation in the Phase 2 retatrutide trial showed early weight regain beginning within the first weeks of stopping. The trajectory suggested regain rates comparable to those seen with tirzepatide and semaglutide, though a 52-week post-discontinuation period was not evaluated 3. No SURMOUNT-4 equivalent exists for retatrutide.

The mechanism of rebound is consistent across incretin-based therapies. Once the drug is removed, appetite suppression ends, gastric emptying returns to baseline, and the counterregulatory hormonal response to weight loss (elevated ghrelin, reduced leptin) resumes. This is a pharmacological reality of the entire drug class, not a flaw specific to either agent.

What Do Physicians Need to Know About Managing Long-Term Therapy?

Long-term therapy management for both drugs follows overlapping but not identical principles.

Dose Titration and Tolerability

Tirzepatide starts at 2.5 mg weekly and escalates in 4-week increments to a maximum of 15 mg. The standard escalation schedule across SURMOUNT trials was 2.5 mg every 4 weeks, reaching 15 mg at week 20 4. Retatrutide's Phase 3 titration schedule has not been finalized publicly, but Phase 2 used a slower ramp to mitigate GI effects.

Patients who cannot tolerate 15 mg tirzepatide may remain at 10 mg with acceptable but somewhat reduced weight loss outcomes. The dose-response relationship in SURMOUNT-1 was clear: 5 mg gave 15.0%, 10 mg gave 19.5%, and 15 mg gave 20.9% at 72 weeks 4.

Monitoring Parameters During Long-Term Treatment

For tirzepatide in type 2 diabetes, HbA1c monitoring every 3 months initially, then every 6 months once stable, aligns with ADA Standards of Care 12. Weight, blood pressure, lipid panel, and hepatic function should be assessed at initiation and at 6-month intervals. For retatrutide, the glucagon agonist component adds a theoretical reason to monitor fasting glucose and liver enzymes more closely during Phase 3 and any post-approval period.

Patient Expectations: What "Durable" Actually Means

Durability in this context means weight maintained over time while on the drug, not after stopping. The Endocrine Society guideline states that obesity is "a chronic, relapsing disease that requires long-term management strategies" 8. Setting patient expectations that these medications require indefinite use to maintain weight loss is a clinical necessity, not a soft recommendation.

A review published in JAMA Internal Medicine found that the concept of a "treatment course" for obesity medications leads to premature discontinuation in 42% of patients within the first year, directly contributing to weight regain 13.

Regulatory and Access Considerations

Tirzepatide holds FDA approval for type 2 diabetes under the brand name Mounjaro and for chronic weight management under the brand name Zepbound (approved November 2023) 14. Retatrutide has no FDA approval as of the publication date of this article. Patients cannot legally obtain retatrutide outside of an active clinical trial or, in some jurisdictions, through compassionate use programs.

Compounding pharmacies have produced tirzepatide during shortage periods; the FDA has issued guidance on this 15. No equivalent compounding pathway exists for retatrutide, as it is not on the FDA drug shortage list and has no approved reference product.

Insurance coverage for Zepbound varies significantly. The Medicare Part D coverage gap and prior authorization requirements mean that out-of-pocket costs for tirzepatide can reach $550 to $1,100 per month without manufacturer savings programs.